Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ELCC 2012 resources

Interview with Dr Ken O'Byrne on the prognostic role of KRAS mutation in non-small cell lung cancer

Dr O'Byrne says this study is a positive step forward in identifying a definite target in a real way

Abstract 164O KRAS mutational status impact progression free survival of patients treated with platinum based chemotherapy in NSCLC
 M.C. Garassino1, S. Veronese1, M. Marabese1, E. Rulli2, G. Farina2, F. Longo3, M.A. Fabbri4, S. Piva2, O. Martelli5, A. Scanni2. (1Milan/IT, 2Milan/IT, 3Rome/IT, 4Viterbo/IT, 5Rome/IT)

Interview with Dr Tony Mok on the clinical implications of the biomarker analysis of the TORCH trial

Dr Mok highlights the strong value of EGFR mutation status when selecting the most effective treatment sequence in advanced NSCLC

Abstract 163O Biomarkers of TORCH Trial on First-line Erlotinib Followed by Second-line Chemotherapy in Advanced Non-Small Cell Lung Cancer Patients
 M.S. Tsao1, C. Gallo2, M. Saieg1, G.D.C. Santos1, V. Gebbia3, F. Perrone2, C. Butts4, F. Ciardiello2, R. Feld5, C. Gridelli6. (1Toronto/CA, 2Napoli/IT, 3Palermo/IT, 4Edmonton, AB/CA, 5Toronto, ON/CA, 6Avellino/IT)

Interview with Dr Carbone on symptom evaluation from a study using the new agent dacomitinib

Dr Carbone stresses the importance of symptom control and quality of life when treating NSCLC patients

Abstract 166O Evaluation of symptom impact of dacomitinib (PF-00299804) vs erlotinib in patients with advanced NSCLC after chemotherapy failure: results from a phase 2 randomized clinical trial
 J. O'Connell1, A. Bottomley2, S.S. Ramalingam3, M. Boyer4, K. Park5, F. Blackhall6, R. Mundayat7, A. Campbell1. (1Groton, CT/US, 2Brussels/BE, 3Atlanta, GA/US, 4Camperdown, NSW/AU, 5Seoul/KR, 6Manchester/UK, 7New York, NY/US)

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.